Appropriateness of psychotropic medication use in a cohort of adolescents with intellectual disability in Queensland, Australia

被引:6
|
作者
Song, Menghuan [1 ]
Ware, Robert S. [1 ,2 ]
Doan, Tan N. [3 ]
McPherson, Lyn [1 ,2 ]
Trollor, Julian N. [4 ]
Harley, David [1 ]
机构
[1] Univ Queensland, Mater Hosp, Queensland Ctr Intellectual & Dev Disabil, Mater Res Inst, Brisbane, Qld, Australia
[2] Griffith Univ, Menzies Hlth Inst Queensland, Nathan, Qld, Australia
[3] Univ Melbourne, Dept Med, Royal Melbourne Hosp, Melbourne, Vic, Australia
[4] Univ New South Wales, Dept Dev Disabil Neuropsychiat, Fac Med, Sydney, NSW, Australia
来源
BJPSYCH OPEN | 2020年 / 6卷 / 06期
关键词
Psychotropic drugs; intellectual disability; off-label use; inappropriate prescribing; adolescent; ADULTS; DRUGS;
D O I
10.1192/bjo.2020.125
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background Psychotropic medications are sometimes used off-label and inappropriately. This may cause harm to adolescents with intellectual disability. However, few studies have analysed off-label or inappropriate prescribing to this group. Aims To examine the appropriateness of psychotropic prescribing to adolescents with intellectual disability living in the community in south-east Queensland, Australia. Method Off-label medication use was determined based on whether the recorded medical condition treated was approved by the Australian Therapeutic Goods Administration. Clinical appropriateness of medication use was determined based on published guidelines and clinical opinion of two authors who specialise in developmental disability medicine (J.N.T. and D.H.). Results We followed 429 adolescents for a median of 4.2 years. A total of 107 participants (24.9%) were prescribed psychotropic medications on at least one occasion. Of these, 88 (82.2%) were prescribed their medication off-label or inappropriately at least once. Off-label or inappropriate use were most commonly associated with challenging behaviours. Conclusions Off-label or inappropriate use of psychotropic medications was common, especially for the management of challenging behaviours. Clinical decision-making accounts for individual patient factors and is made based on clinical experience as well as scientific evidence, whereas label indications are developed for regulatory purposes and, although appropriate at a population level, cannot encompass the foregoing considerations. Education for clinicians and other staff caring for people with intellectual disability, and a patient-centred approach to prescribing with involvement of families should encourage appropriate prescribing. The effect of the National Disability Insurance Scheme on the appropriateness of psychotropic medication prescribing should be investigated.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Use of Psychotropic Drugs in People with Intellectual Disability in Extremadura, Spain
    Alvarez, Ana Maria Serna
    Garcia-Baamonde, Maria Elena
    Guerrero-Molina, Monica
    Manso, Juan Manuel Moreno
    ACTA COLOMBIANA DE PSICOLOGIA, 2023, 26 (01): : 200 - 213
  • [32] A structured medication review tool to promote psychotropic medication optimisation for adults with intellectual disability: feasibility study
    Sheehan, Rory
    Strydom, Andre
    Marston, Louise
    Morant, Nicola
    Fiori, Federico
    Santosh, Paramala
    Hassiotis, Angela
    BMJ OPEN, 2019, 9 (12):
  • [33] Use of medication for challenging behaviour in people with intellectual disability
    Glover, Gyles
    Bernard, Sarah
    Branford, David
    Holland, Anthony
    Strydom, Andre
    BRITISH JOURNAL OF PSYCHIATRY, 2014, 205 (01) : 6 - 7
  • [34] Psychotropic medication for problem behaviours in intellectual disability and autism spectrum disorder: the need for caution
    Bertelli, Marco O.
    BJPSYCH ADVANCES, 2023, : 334 - 336
  • [35] AUSTRALIAN COALFACE PERSPECTIVES OF PSYCHOTROPIC MEDICATION USED FOR CHEMICAL RESTRAINT OF ADULTS WITH INTELLECTUAL DISABILITY
    Edwards, N.
    King, J.
    Williams, K.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2015, 59 : 116 - 116
  • [37] Psychotropic Medication Use in Children and Adolescents: Review of Outpatient Treatments
    Usta, Mirac Baris
    Gumus, Yusuf Yasin
    Aral, Armagan
    Say, Gokce Nur
    Karabekiroglu, Koray
    DUSUNEN ADAM-JOURNAL OF PSYCHIATRY AND NEUROLOGICAL SCIENCES, 2018, 31 (01): : 72 - 78
  • [38] Use of Psychotropic Medication in Children and Adolescents With Autism Spectrum Disorders
    Coury, Daniel L.
    Anagnostou, Evdokia
    Manning-Courtney, Patricia
    Reynolds, Ann
    Cole, Lynn
    Mccoy, Robin
    Whitaker, Agnes
    Perrin, James M.
    PEDIATRICS, 2012, 130 : S69 - S76
  • [39] Psychotropic medication use in children and adolescents:: A study from France
    Sevilla-Dedieu, Christine
    Kovess-Masfety, Viviane
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2008, 18 (03) : 281 - 289
  • [40] Recent trends in psychotropic medication use in children and adolescents in Ireland
    Parkin, Rebecca
    Bennett, Kathleen
    Nicholas, Fiona Mc
    Hayden, John C.
    EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2025, 34 (03) : 997 - 1009